Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04774380 Active, not recruiting - Clinical trials for Extensive-stage Small Cell Lung Cancer

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

LUMINANCE
Start date: November 11, 2021
Phase: Phase 3
Study type: Interventional

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

NCT ID: NCT04773275 Terminated - Clinical trials for Cancer of Lung, Kidney or Liver

A Clinical Evaluation of the Aliyaâ„¢ System in Late Stage Cancer

INCITE LS
Start date: May 9, 2022
Phase: N/A
Study type: Interventional

A prospective, single-arm, non-randomized, multi-center, open-label study following patients to 1 year. The study is designed to evaluate the safety and clinical utility of Pulsed Electric Field (PEF) treatment of advanced stage or metastatic cancer following progression on immunotherapy.

NCT ID: NCT04772287 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection. To evaluate the effectiveness and safety of toripalimab compared with placebo combined with platinum-containing dual-drug chemotherapy.

NCT ID: NCT04771520 Recruiting - Metastatic Melanoma Clinical Trials

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Avapritinib may help to control the growth of malignant solid tumors.

NCT ID: NCT04768296 Completed - Clinical trials for Small-cell Lung Cancer

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main part. The safety run-in part will be conducted in Japan.

NCT ID: NCT04765059 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

COMPEL
Start date: September 12, 2021
Phase: Phase 3
Study type: Interventional

The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.

NCT ID: NCT04762459 Enrolling by invitation - Clinical trials for Non-small Cell Lung Carcinoma

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

APEX
Start date: August 1, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, open label, phase III study.

NCT ID: NCT04762199 Recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Start date: February 24, 2021
Phase: Phase 1
Study type: Interventional

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04762030 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Start date: February 8, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.

NCT ID: NCT04759651 Recruiting - Lung Cancer Clinical Trials

Sleep Disorders in Patients With Suspected Lung Cancer Before and After Thoracic Surgery

Start date: June 1, 2021
Phase:
Study type: Observational

The main aim of this study is to prospectively evaluate the occurrence of sleep disorders in patients undergoing thoracic surgery due to the preliminary diagnosis of lung cancer. Secondary aims include anxiety, depressive mood and functional outcomes before and 3 months after the intervention.